

LETTER

Open Access



Cortisol total/CRP ratio for the prediction of hospital-acquired pneumonia and initiation of corticosteroid therapy in traumatic brain-injured patients

Linpei Jia^{1*} and Hongliang Zhang^{2*}

Bouras and colleagues attempted to use the cortisol total/CRP ratio for the prediction of hospital-acquired pneumonia (HAP) and initiation of corticosteroid therapy in patients with severe traumatic brain injury (TBI) and with adrenal insufficiency [1]. They found that a cortisol total/CRP ratio > 3 upon admission may predict the development of HAP in patients with severe TBI [1]. The study is interesting, while we have some concerns about the study design and interpretation of the data.

The CORTI-TC trial [2] revealed that low-dose hydrocortisone with fludrocortisone did not improve the outcome of patients with TBI. Although the relatively small sample size is considered as a reason for negative findings, we believe that stratified analyses are more important for such a study. HAP is a form of nosocomial pneumonia, which is distinct from VAP [3]. In a published guideline from the Infectious Diseases Society of America and the American Thoracic Society, the term HAP denotes an episode of pneumonia not associated with mechanical ventilation [4, 5]. As acknowledged also by the authors, mechanical ventilation promotes a specific histological pattern of pneumonia [1]. Hence, patients with HAP and ventilator-associated pneumonia (VAP) should be categorized into two distinct groups. All cases of recorded HAP were VAP [1], which means all these patients received mechanical ventilation. Thus, we are eager to know about

the patients without HAP. What is the percentage of mechanical ventilation use in these patients?

In this post hoc analysis of the CORTI-TC trial, the authors may hypothesize that the cortisol total/CRP ratio may or may not predict HAP. However, HAP is more associated with disease severity per se, e.g., consciousness state, prophylactic use of antibiotics, duration of intensive care, and mechanical ventilation, with many comorbidities potentially acting as confounding factors. We are then interested to know about the prophylactic use of antibiotics in the CORTI-TC trial.

Seemingly, results from Table 1 and Table 2 are conflicting [1]. Whereas in Table 1, up to 20% patients without HAP (versus 5.6% in those without HAP) had body temperature $> 39.0^{\circ}\text{C}$ upon admission, in Table 2, multivariate analysis revealed that body temperature $> 39.0^{\circ}\text{C}$ was closely associated with HAP [1]. Besides, the unit of the leucocyte count in Table 1 is grams per liter, which should be typographical errors.

In summary, HAP is common after TBI and closely associated with its outcome. More studies are warranted to seek surrogate biomarkers to predict the occurrence of HAP.

Acknowledgements

None.

Authors' contributions

LJ and HZ conceived the topic. LJ drafted the manuscript. HZ critically revised the manuscript. Both authors read and approved the final manuscript.

Authors' information

Nil.

* Correspondence: anny_069@163.com; drzhl@hotmail.com
This comment refers to the article available at <https://doi.org/10.1186/s13054-019-2680-6>.

¹Department of Nephrology, Xuanwu Hospital, Capital Medical University, Changchun Street 45#, Beijing 100053, China

²Department of Life Sciences, The National Natural Science Foundation of China, Shuangqing Road 83#, Beijing 100085, China



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Funding

None.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Both authors approved the final version for submission and publication.

Competing interests

The authors declare that they have no competing interests.

Received: 6 February 2020 Accepted: 19 February 2020

Published online: 04 March 2020

References

1. Bouras M, Roquilly A, Mahé PJ, et al. Cortisol total/CRP ratio for the prediction of hospital-acquired pneumonia and initiation of corticosteroid therapy in traumatic brain-injured patients. *Crit Care*. 2019;23:394.
2. Asehnoune K, Seguin P, Allary J, et al. Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial. *Lancet Respir Med*. 2014;2:706–16.
3. Niederman MS. Antibiotic treatment of hospital-acquired pneumonia: is it different from ventilator-associated pneumonia? *Curr Opin Crit Care*. 2018; 24:353–60.
4. Kalil AC, Metersky ML, Klompas M, et al. Executive summary: management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis*. 2016;63:575–82.
5. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis*. 2016;63:e61–e111.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.